ADXN

Addex Therapeutics Ltd

• Reuters·03/25 20:04

  Addex Therapeutics files Form 3 initial beneficial ownership statement; Chief Medical Officer and director Roger Mills reports 785,976 common shares

• Reuters·03/25 20:03

  Addex Therapeutics files Form 3 initial beneficial ownership statement; Director Vincent Michael Lawton reports 2.5 million common shares

• Reuters·03/25 20:03

  Addex Therapeutics files Form 3 initial beneficial ownership statement; Principal Accounting Officer Lenaic Nathanael Teyssedou reports stock options with exercise prices of $0.166 and $0.055

• Reuters·03/25 20:02

  Addex Therapeutics files Form 3; Head of Translational Science Mikhail Kalinichev reports 306,765 common shares

• Reuters·03/25 20:02

  Addex Therapeutics files Form 3; Director Raymond George Hill reports 1.4 million common shares owned

• Benzinga·03/19 12:06

  12 Health Care Stocks Moving In Thursday's Pre-Market Session

• TipRanks·03/18 16:05

  Addex Therapeutics Ltd – ADR trading resumes

• TipRanks·03/18 16:02

  Addex Therapeutics Ltd – ADR trading halted, volatility trading pause

• Reuters·03/18 15:07

  Addex Therapeutics CEO Timothy Mark Dyer files Form 3 initial beneficial ownership statement

• Reuters·03/18 15:07

  Addex Therapeutics Director Jason Raleigh Nunn Files Initial Beneficial Ownership Statement

• Reuters·03/18 15:07

  Addex Therapeutics Ltd. Director Isaac Manke Files Initial Beneficial Ownership Statement

• Benzinga·03/11 21:06

  12 Health Care Stocks Moving In Wednesday's After-Market Session

• TipRanks·02/03 10:40

  Addex publishes negative allosteric modulators data in Molecular Psychiatry

• Reuters·02/03 06:00

  Addex Therapeutics präsentiert präklinische Daten zu neuem Ansatz bei Angststörungen

• Reuters·02/03 06:00

  Addex Therapeutics Unveils mGlu7 Modulator as Potential Game-Changer for Anxiety and PTSD Treatment